After Protracted Sell-Off, Amphastar Looks Like A Value Pick

Group 1 - The article discusses Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) and its potential for growth following the acquisition of BAQSIMI, despite market pessimism affecting its stock performance [1] - The author previously labeled AMPH as a buy, indicating expectations for growth that have not materialized due to broader healthcare industry challenges [1] Group 2 - The author has extensive experience in investment analysis, focusing on identifying underappreciated companies that can return value to investors [1]